Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411703 | 0.90 | KDM4E (0.43) | CYP2D6CYP2C19MTNR1AMTNR1BKDM4E | |
| SCHEMBL3122891 | 0.87 | CYP2D6 (0.57) | CYP2D6CYP2C19BACE1 | |
| SCHEMBL15834120 | 0.81 | KISS1R (0.47) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL13541018 | 0.81 | KISS1R (0.47) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL5708313 | 0.79 | SLC22A6 (0.52) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL5708314 | 0.79 | SLC22A6 (0.52) | MTNR1AMTNR1BKDM4EMAPK1HIF1A | |
| SCHEMBL15835816 | 0.78 | — | — | |
| SCHEMBL16015603 | 0.78 | — | — | |
| SCHEMBL1436205 | 0.78 | — | — | |
| SCHEMBL5206473 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989097-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2016-03-02 | — | — | EP | claimed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | claimed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| EP-2989097-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | CYP3A5, SBDS, MLYCD | CYP2D6 88/4885CYP2C19 15/4885MTNR1A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.